X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Fulford India with Novartis - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

FULFORD INDIA vs NOVARTIS - Comparison Results

FULFORD INDIA    Change

Fulford (India) Limited is an Indian affiliate of Schering-Plough Corporation, USA. The company has presence in oncology, virology and cardiovascular segments. In FY06 the topline of the company grew by 15.5% to Rs. 1519 m from Rs. 1279 m in FY05. PA... More

NOVARTIS 
   Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    FULFORD INDIA NOVARTIS FULFORD INDIA/
NOVARTIS
 
P/E (TTM) x 398.8 360.4 110.7% View Chart
P/BV x 6.2 40.0 15.6% View Chart
Dividend Yield % 0.1 1.1 7.4%  

Financials

 FULFORD INDIA   NOVARTIS
EQUITY SHARE DATA
    FULFORD INDIA
Mar-14
NOVARTIS
Mar-18
FULFORD INDIA/
NOVARTIS
5-Yr Chart
Click to enlarge
High Rs942758 124.3%   
Low Rs450579 77.7%   
Sales per share (Unadj.) Rs691.4228.4 302.7%  
Earnings per share (Unadj.) Rs11.531.7 36.1%  
Cash flow per share (Unadj.) Rs15.432.8 46.9%  
Dividends per share (Unadj.) Rs2.0010.00 20.0%  
Dividend yield (eoy) %0.31.5 19.2%  
Book value per share (Unadj.) Rs380.0297.1 127.9%  
Shares outstanding (eoy) m3.9024.69 15.8%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.02.9 34.4%   
Avg P/E ratio x60.721.1 288.3%  
P/CF ratio (eoy) x45.320.4 222.1%  
Price / Book Value ratio x1.82.2 81.4%  
Dividend payout %17.431.5 55.4%   
Avg Mkt Cap Rs m2,71416,505 16.4%   
No. of employees `0000.40.7 66.5%   
Total wages/salary Rs m5051,445 34.9%   
Avg. sales/employee Rs Th6,073.08,441.3 71.9%   
Avg. wages/employee Rs Th1,137.42,163.6 52.6%   
Avg. net profit/employee Rs Th100.71,173.1 8.6%   
INCOME DATA
Net Sales Rs m2,6965,639 47.8%  
Other income Rs m1251,718 7.3%   
Total revenues Rs m2,8227,357 38.4%   
Gross profit Rs m-46-63 74.2%  
Depreciation Rs m1525 60.1%   
Interest Rs m1055 17.2%   
Profit before tax Rs m541,575 3.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m10792 1.2%   
Profit after tax Rs m45784 5.7%  
Gross profit margin %-1.7-1.1 155.3%  
Effective tax rate %17.750.3 35.2%   
Net profit margin %1.713.9 11.9%  
BALANCE SHEET DATA
Current assets Rs m1,7389,522 18.3%   
Current liabilities Rs m5453,296 16.5%   
Net working cap to sales %44.3110.4 40.1%  
Current ratio x3.22.9 110.5%  
Inventory Days Days4837 132.4%  
Debtors Days Days428 15.1%  
Net fixed assets Rs m1246 25.9%   
Share capital Rs m39123 31.6%   
"Free" reserves Rs m1,4437,213 20.0%   
Net worth Rs m1,4827,336 20.2%   
Long term debt Rs m00-   
Total assets Rs m2,07711,105 18.7%  
Interest coverage x6.729.5 22.8%   
Debt to equity ratio x00-  
Sales to assets ratio x1.30.5 255.7%   
Return on assets %2.67.6 34.5%  
Return on equity %3.010.7 28.2%  
Return on capital %4.322.2 19.4%  
Exports to sales %00-   
Imports to sales %24.50-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs m659NA-   
Fx inflow Rs m1761 28.4%   
Fx outflow Rs m6733,630 18.5%   
Net fx Rs m-656-3,570 18.4%   
CASH FLOW
From Operations Rs m901,610 5.6%  
From Investments Rs m105687 15.2%  
From Financial Activity Rs m-14-2,677 0.5%  
Net Cashflow Rs m181-380 -47.6%  

Share Holding

Indian Promoters % 0.0 0.0 -  
Foreign collaborators % 75.0 75.0 100.0%  
Indian inst/Mut Fund % 3.8 2.0 190.0%  
FIIs % 0.1 1.6 6.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 21.2 21.5 98.6%  
Shareholders   4,783 41,647 11.5%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare FULFORD INDIA With:   CADILA HEALTHCARE  TTK HEALTHCARE  ORCHID PHARMA LTD  DISHMAN PHARMA  J.B.CHEMICALS  

Compare FULFORD INDIA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Slumps Over 290 Points; Realty and PSU Stocks Witness Selling(Closing)

After opening the day on a negative note, share markets in India continued their downtrend throughout the day and ended in red.

Related Views on News

NOVARTIS Announces Quarterly Results (1QFY19); Net Profit Up 42.2% (Quarterly Result Update)

Jul 30, 2018 | Updated on Jul 30, 2018

For the quarter ended June 2018, NOVARTIS has posted a net profit of Rs 100 m (up 42.2% YoY). Sales on the other hand came in at Rs 1 bn (up 20.3% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

NOVARTIS Announces Quarterly Results (4QFY18); Net Profit Up 809.6% (Quarterly Result Update)

Jul 20, 2018 | Updated on Jul 20, 2018

For the quarter ended March 2018, NOVARTIS has posted a net profit of Rs 265 m (up 809.6% YoY). Sales on the other hand came in at Rs 1 bn (down 13.9% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

In a Crisis, if Petrol Prices Hit Rs 100, This Stock Could Be a Good Buy(The 5 Minute Wrapup)

Sep 6, 2018

The rise in the crude oil price is a major reason for the fall in the market. If crude oil prices keep on rising, what will happen to stocks?

As the Rupee Takes a Record Plunge, These Pharma Stocks Gain the Most(Sector Info)

Sep 5, 2018

Most pharma stocks were trading with gains amid rupee's fresh fall. Does that mean pharma stocks are back in vogue?

Why Arun Jaitley's Demonetisation Defence Doesn't Add Up(Vivek Kaul's Diary)

Sep 5, 2018

The tax collected has gone up a little but the question is at what cost.

The Cream of Small Cap Stocks(Profit Hunter)

Sep 5, 2018

Akin to skimming the cream off milk, one needs to learn to skim the cream off small cap stocks.

The Secret Of Mirae Asset India Equity Fund's Increasing Popularity(Outside View)

Sep 7, 2018

The prudent investment strategies followed at the fund house has helped Mirae Asset India Equity Fund earn a tag of being a consistent performer, which is in turn gaining popularity among investors.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

FULFORD INDIA SHARE PRICE


Jul 30, 2015 (Close)

TRACK FULFORD INDIA

  • Track your investment in FULFORD INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

FULFORD INDIA 5-YR ANALYSIS

COMPARE FULFORD INDIA WITH

MARKET STATS